drugset / Trial / NCT07397338
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.
Timeline
- Start
- 2026-01-30
- Primary completion
- 2029-05
- Completion
- 2029-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Cetuximab | Monoclonal antibody | — | Intravenous |
| Subject | Cisplatin | Other / unclassified | — | Intravenous |
| Subject | Elironrasib | Unknown | — | Oral |
| Subject | Ivonescimab | Monoclonal antibody | — | Intravenous |
| Subject | Pemetrexed | Small molecule | — | Intravenous |
| Subject | RMC-9805 | Unknown | — | Oral |
| Subject | daraxonrasib | Small molecule | — | Oral |